MTOR and chronic kidney disease: Our study had other analyses to SQYSF network pharmacology, and then the outcomes pinpointed those pathways relevant to SQYSF within CKD treatment, which are the signaling pathways of Tyrosine metabolism, Calcium, mTOR, AMPK, Toll-like receptor, HIF-1 and the pathways of the PD-L1 expression and PD-1 checkpoint in cancer.